- Noren T, Akerlund T, Back E, et al. Molecular epidemiology of hospital-associated and community-
acquired Clostridium difficile infection in a Swedish county. J Clin Microbiol 2004; 42(8):3635–3643. - Mandell G, Bennet J, Dolin R. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia:
Elsevier Churchill Livingstone, 2005. - Shim JK, Johnson S, Samore MH, et al. Primary symptomless colonisation by Clostridium difficile and
decreased risk of subsequent diarrhoea. Lancet 1998; 351(9103):633–636. - Owens RC Jr., Donskey CJ, Gaynes RP, et al. Antimicrobial-associated risk factors for Clostridium
difficile infection. Clin Infect Dis 2008; 46(suppl 1):S19–S31. - Pultz NJ, Donskey CJ. Effect of antibiotic treatment on growth of and toxin production by Clostridium
difficile in the cecal contents of mice. Antimicrob Agents Chemother 2005; 49(8):3529–3532. - Johnson S, Samore MH, Farrow KA, et al. Epidemics of diarrhea caused by a clindamycin-resistant
strain of Clostridium difficile in four hospitals. N Engl J Med 1999; 341(22):1645–1651. - Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40(1):1–15.
- Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin
Infect Dis 2008; 46(suppl 1):S12–S18. - Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346(5):334–339.
- Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of
IgG antibody against toxin A. N Engl J Med 2000; 342(6):390–397. - Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection
against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357(9251):189–193. - Jiang ZD, Dupont HL, Garey K, et al. A common polymorphism in the interleukin 8 gene promoter is
associated with Clostridium difficile diarrhea. Am J Gastroenterol 2006; 101(5):1112–1116. - Bliss DZ, Johnson S, Savik K, et al. Acquisition of Clostridium difficile and Clostridium difficile-
associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 1998; 129(12):
1012–1019. - Lowe DO, Mamdani MM, Kopp A, et al. Proton pump inhibitors and hospitalization for Clostridium
difficile-associated disease: a population-based study. Clin Infect Dis 2006; 43(10):1272–1276. - Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients
prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171(1):33–38. - Guerrant RL, Steiner TS, Lima AA, et al. How intestinal bacteria cause disease. J Infect Dis 1999; 179
(suppl 2):S331–S337. - Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile—associated diarrhea: A review. Arch
Intern Med 2001; 161(4):525–533. - Wolf LE, Gorbach SL, Granowitz EV. Extraintestinal Clostridium difficile: 10 years’ experience at a
tertiary-care hospital. Mayo Clin Proc 1998; 73(10):943–947. - Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile
associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366
(9491):1079–1084. - McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium
difficile. N Engl J Med 2005; 353(23):2433–2441. - Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the
putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates.
J Clin Microbiol 2002; 40(9):3470–3475. - Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor
for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect
Dis 2005; 41(9):1254–1260. - Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated
and increasing cause of death and complications. Ann Surg 2002; 235(3):363–372. - Wanahita A, Goldsmith EA, Musher DM. Conditions associated with leukocytosis in a tertiary care
hospital, with particular attention to the role of infection caused by clostridium difficile. Clin Infect
Dis 2002; 34(12):1585–1592. - Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics
of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect
Dis 1997; 24(3):324–333. - Kawamoto S, Horton KM, Fishman EK. Pseudomembranous colitis: spectrum of imaging findings
with clinical and pathologic correlation. Radiographics 1999; 19(4):887–897. - Yassin SF, Young-Fadok TM, Zein NN, et al. Clostridium difficile-associated diarrhea and colitis.
Mayo Clin Proc 2001; 76(7):725–730. - Missaghi B, Valenti AJ, Owens RC Jr. Clostridium difficile Infection: a critical overview. Curr Infect
Dis Rep 2008; 10(3):165–173.
286 Hjalmarson and Gorbach